CERo Therapeutics Holdings (CERo Therapeutics Holdings) Change In Inventory : $0.00 Mil (TTM As of Dec. 2022)

View and export this data going back to 2024. Start your Free Trial

What is CERo Therapeutics Holdings Change In Inventory?

CERo Therapeutics Holdings's change in inventory for the quarter that ended in Dec. 2022 was $0.00 Mil. It means CERo Therapeutics Holdings's inventory stayed the same from Dec. 2021 to Dec. 2022 .

CERo Therapeutics Holdings's change in inventory for the fiscal year that ended in Dec. 2022 was $0.00 Mil. It means CERo Therapeutics Holdings's inventory stayed the same from Dec. 2021 to Dec. 2022 .

CERo Therapeutics Holdings's Total Inventories for the quarter that ended in Dec. 2022 was $0.00 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

CERo Therapeutics Holdings Change In Inventory Historical Data

The historical data trend for CERo Therapeutics Holdings's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CERo Therapeutics Holdings Change In Inventory Chart

CERo Therapeutics Holdings Annual Data

Trend

Dec21

Dec22

Change In Inventory

CERo Therapeutics Holdings Semi-Annual Data
	Dec21	Dec22
Change In Inventory	-	-

CERo Therapeutics Holdings Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Change In Inventory for the trailing twelve months (TTM) ended in Dec. 2022 was $0.00 Mil.

CERo Therapeutics Holdings (NAS:CERO) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

CERo Therapeutics Holdings's Days Inventory for the quarter that ended in is calculated as:

Days Inventory	=	Average Total Inventories	/	Cost of Goods Sold	*	Days in Period
	=	0	/	0	*	365 / 2
	=	N/A

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

CERo Therapeutics Holdings's Inventory Turnover for the quarter that ended in Dec. 2022 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	0	/	0
	=	N/A

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

CERo Therapeutics Holdings's Inventory to Revenue for the quarter that ended in Dec. 2022 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	0	/	0
	=	N/A

CERo Therapeutics Holdings Change In Inventory Related Terms

Thank you for viewing the detailed overview of CERo Therapeutics Holdings's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

CERo Therapeutics Holdings (CERo Therapeutics Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CERo Therapeutics Holdings Inc (NAS:CERO) » Definitions » Change In Inventory

Comparable Companies

Traded in Other Exchanges

N/A

Address

201 Haskings Way, Suite 230, San Francisco, CA, USA, 94080

Website

https://www.cero.bio

CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.

CERo Therapeutics Holdings (CERo Therapeutics Holdings) Headlines

From GuruFocus

CERo Therapeutics, Inc. Announces Publication of Preclinical Research Supporting the Use of Its Clinical Candidate CER-1236 to Treat AML Patients

By Business Wire • 03-07-2024